| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2011-05-17 | Advanced BioHealing (USA) | Shire (UK - USA) | $750 million in cash | Regenerative medicine |
| 2011-05-09 | Elan Drug Technologies (formulation and manufacturing business unit of Elan – Ireland) | Alkermes (Ireland - USA) | $960 Million (€668.7 million) | CNS |
| 2011-05-02 | Cephalon (USA) | Teva Pharmaceuticals (Israel) | $6.8 billion (€10.1 billion) | Specialty pharma |
| 2011-05-02 | Nordic Vaccine (Denmark) | Isconova (Sweden) | SEK 4,032,228 (€ 446 600) | Vaccines |
| 2011-04-27 | Lab Research (Canada) | CIT Safety & Health Research Laboratories (CIT) (France) | undisclosed | CRO |
| 2011-04-12 | LAB Research (Canada) | CIT (France) | undisclosed | CRO |
| 2011-04-11 | Biophausia (Sweden) | Medivir (Sweden) | undisclosed | Specialty pharma |
| 2011-04-06 | Astex Therapeutics (UK) | SuperGen (USA) | $55 million (€38.3 million) | Cancer Oncology |
| 2011-03-24 | Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA) | Boehringer Ingelheim (Germany) | undisclosed | Production |
| 2011-03-22 | Zhejiang Tianyuan (China) | Novartis (Switzerland) | undisclosed | Vaccines |
| 2011-03-15 | Theragenics (USA) | Eckert & Ziegler Strahlen- und Medizintechnik (Germany) | $74 million | |
| 2011-03-15 | PVT (Germany) | Roche (Switzerland) | € 65 million and up to € 20 million upon reaching performance-related milestones. | clinical diagnostics |
| 2011-03-08 | Crucell (The Netherlands) | Johson&Johnson - J&J (USA) | €1.75 billion | Vaccines |
| 2011-03-02 | veterinary business of Riemser Arzneimittel (Germany) | Ecuphar (Belgium) | Veterinary medicine |
|
| 2011-02-28 | Avogadro (France) | Amatsi (France) | undisclosed | Drug development services |
| 2011-02-25 | Cellerix (Spain) | Tigenix (Belgium) | stem cell |
|
| 2011-02-24 | Lancaster Laboratories (USA) | Eurofins Scientific (France) | approximately $ 200 million | Pharmaceutical product testing services and cGMP Quality Control |
| 2011-02-22 | iNovia (Sweden) | Kancera (Sweden) | undisclosed | services |
| 2011-02-21 | Prostrakan (UK) | Kyowa Hakko Kirin (Japan) | £ 292 million(€ 345,3 million) | specialty pharma |
| 2011-02-16 | Genzyme (USA) | Sanofi Aventis (France) | $ 20,1 billion | Rare diseases |
